• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

EMX2OS 在胃癌中发挥预后相关增强子 RNA 的作用。

EMX2OS plays a prognosis-associated enhancer RNA role in gastric cancer.

机构信息

Department of Emergency, Zhuzhou Central Hospital, Zhuzhou, China.

Department of Neurology, Zhuzhou Central Hospital, Zhuzhou, China.

出版信息

Medicine (Baltimore). 2021 Oct 15;100(41):e27535. doi: 10.1097/MD.0000000000027535.

DOI:10.1097/MD.0000000000027535
PMID:34731149
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8519253/
Abstract

Enhancer RNAs (eRNAs), a subclass of lncRNAs, are derived from enhancer regions. The function of eRNAs has been reported by many previous studies. However, the role of eRNAs in gastric cancer, especially the prognosis-associated eRNAs, has not been studied yet.In this study, we have used a novel approach to screened key eRNAs in gastric cancer. Kaplan-Meier correlation analysis and Co-expression analysis were used to find the most significant survival-associated eRNAs. Enrichment analysis is applied to explore the key functions and pathways of screened eRNAs. The correlation and survival analysis are used to evaluate targeted genes in the pan-cancer analysisA total of 63 prognostic-associated eRNAs in gastric cancer were identified, the top 6 eRNAs were LINC01714, ZNF192P1, AC079760.2, LINC01645, EMX2OS, and AC114489.2. The correlation analysis demonstrated the top 10 screened eRNAs and their targeted genes. The results demonstrated that EMX2OS was ranked as the top eRNA according to the results of the Kaplan-Meier analysis. The correlation analysis demonstrated that eRNA EMX2OS is correlated with age, grade, stage, and cancer status. The pan-cancer analysis demonstrated that EMX2OS was associated with poor survival outcomes in adrenocortical carcinoma, cervical squamous cell carcinoma and endocervical adenocarcinoma, kidney renal clear cell carcinoma, stomach adenocarcinoma, and uveal melanoma.In this study, survival-related eRNAs were screened and the correlation between survival-related eRNAs and their targeted genes was demonstrated. EMX2OS plays a prognosis-associated eRNA role in gastric cancer, which might be a novel therapeutic target in clinical practice.

摘要

增强子 RNA(eRNAs)是 lncRNA 的一个子类,来源于增强子区域。许多先前的研究已经报道了 eRNAs 的功能。然而,eRNAs 在胃癌中的作用,特别是与预后相关的 eRNAs,尚未得到研究。在这项研究中,我们使用了一种新的方法来筛选胃癌中的关键 eRNAs。Kaplan-Meier 相关性分析和共表达分析用于寻找最显著的与生存相关的 eRNAs。富集分析用于探索筛选出的 eRNAs 的关键功能和途径。相关性和生存分析用于评估泛癌分析中靶向基因。共鉴定出 63 个与胃癌相关的预后相关 eRNAs,前 6 个 eRNAs 是 LINC01714、ZNF192P1、AC079760.2、LINC01645、EMX2OS 和 AC114489.2。相关性分析显示了前 10 个筛选出的 eRNAs 及其靶向基因。结果表明,根据 Kaplan-Meier 分析结果,EMX2OS 是排名最高的 eRNA。相关性分析表明,eRNA EMX2OS 与年龄、分级、分期和癌症状态相关。泛癌分析表明,EMX2OS 与肾上腺皮质癌、宫颈鳞状细胞癌和宫颈内膜腺癌、肾透明细胞癌、胃腺癌和葡萄膜黑色素瘤的不良生存结局相关。在这项研究中,筛选了与生存相关的 eRNAs,并证明了与生存相关的 eRNAs 及其靶向基因之间的相关性。EMX2OS 在胃癌中发挥着与预后相关的 eRNA 作用,这可能是临床实践中的一个新的治疗靶点。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7c86/8519253/8050bedf699e/medi-100-e27535-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7c86/8519253/ee48c99895bd/medi-100-e27535-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7c86/8519253/542a2c3c8b01/medi-100-e27535-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7c86/8519253/e8c7946f292a/medi-100-e27535-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7c86/8519253/d3c8459c34b1/medi-100-e27535-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7c86/8519253/0ae1449fa314/medi-100-e27535-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7c86/8519253/8050bedf699e/medi-100-e27535-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7c86/8519253/ee48c99895bd/medi-100-e27535-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7c86/8519253/542a2c3c8b01/medi-100-e27535-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7c86/8519253/e8c7946f292a/medi-100-e27535-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7c86/8519253/d3c8459c34b1/medi-100-e27535-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7c86/8519253/0ae1449fa314/medi-100-e27535-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7c86/8519253/8050bedf699e/medi-100-e27535-g006.jpg

相似文献

1
EMX2OS plays a prognosis-associated enhancer RNA role in gastric cancer.EMX2OS 在胃癌中发挥预后相关增强子 RNA 的作用。
Medicine (Baltimore). 2021 Oct 15;100(41):e27535. doi: 10.1097/MD.0000000000027535.
2
Downregulation of enhancer RNA EMX2OS is associated with poor prognosis in kidney renal clear cell carcinoma.增强子 RNA EMX2OS 的下调与肾透明细胞癌的不良预后相关。
Aging (Albany NY). 2020 Nov 25;12(24):25865-25877. doi: 10.18632/aging.202151.
3
The downregulation of lncRNA EMX2OS might independently predict shorter recurrence-free survival of classical papillary thyroid cancer.lncRNA EMX2OS 的下调可能独立预测经典型甲状腺乳头状癌更短的无复发生存期。
PLoS One. 2018 Dec 21;13(12):e0209338. doi: 10.1371/journal.pone.0209338. eCollection 2018.
4
Comprehensive Analysis of Enhancer RNAs Identifies LINC00689 and ELFN1-AS1 as Novel Prognostic Biomarkers in Uveal Melanoma.全面分析增强子 RNA 鉴定出 LINC00689 和 ELFN1-AS1 作为葡萄膜黑色素瘤的新型预后生物标志物。
Dis Markers. 2022 Feb 23;2022:5994800. doi: 10.1155/2022/5994800. eCollection 2022.
5
DCP1A is an unfavorable prognostic-related enhancer RNA in hepatocellular carcinoma.DCP1A 是肝癌中一种预后不良的相关增强子 RNA。
Aging (Albany NY). 2021 Oct 4;13(19):23020-23035. doi: 10.18632/aging.203593.
6
TBX5-AS1, an enhancer RNA, is a potential novel prognostic biomarker for lung adenocarcinoma.TBX5-AS1,一种增强子 RNA,是肺腺癌潜在的新型预后生物标志物。
BMC Cancer. 2021 Jul 9;21(1):794. doi: 10.1186/s12885-021-08517-w.
7
Comprehensive characterization of functional eRNAs in lung adenocarcinoma reveals novel regulators and a prognosis-related molecular subtype.肺腺癌中功能性增强子RNA的综合表征揭示了新的调节因子和一种预后相关的分子亚型。
Theranostics. 2020 Sep 14;10(24):11264-11277. doi: 10.7150/thno.47039. eCollection 2020.
8
eRNAs and Superenhancer lncRNAs Are Functional in Human Prostate Cancer.eRNAs 和超级增强子长非编码 RNA 在人类前列腺癌中具有功能。
Dis Markers. 2020 Sep 22;2020:8847986. doi: 10.1155/2020/8847986. eCollection 2020.
9
Role of SLC44A3-AS1 Enhancer RNA in Esophageal Cancer Prognosis.SLC44A3-AS1 增强子 RNA 在食管癌预后中的作用。
J Coll Physicians Surg Pak. 2023 Sep;33(9):964-971. doi: 10.29271/jcpsp.2023.09.964.
10
Functional roles of antisense enhancer RNA for promoting prostate cancer progression.反义增强 RNA 在促进前列腺癌进展中的功能作用。
Theranostics. 2021 Jan 1;11(4):1780-1794. doi: 10.7150/thno.51931. eCollection 2021.

引用本文的文献

1
A novel stemness-related lncRNA signature predicts prognosis, immune infiltration and drug sensitivity of clear cell renal cell carcinoma.一种新型的干性相关长链非编码RNA特征可预测透明细胞肾细胞癌的预后、免疫浸润和药物敏感性。
J Transl Med. 2025 Feb 27;23(1):238. doi: 10.1186/s12967-025-06251-6.
2
Long non-coding RNAs as potential biomarkers or therapeutic targets in gastric cancer.长链非编码RNA作为胃癌潜在的生物标志物或治疗靶点
Gastroenterol Hepatol Bed Bench. 2023;16(3):297-306. doi: 10.22037/ghfbb.v16i2.2701.
3
A novel necroptosis-related long noncoding RNA model for predicting clinical features, immune characteristics, and therapeutic response in clear cell renal cell carcinoma.
一种新型的坏死相关长非编码 RNA 模型,用于预测透明细胞肾细胞癌的临床特征、免疫特征和治疗反应。
Front Immunol. 2023 Aug 2;14:1230267. doi: 10.3389/fimmu.2023.1230267. eCollection 2023.
4
Construction of stomach adenocarcinoma prognostic signature based on anoikis-related lncRNAs and clinical significance.基于失巢凋亡相关 lncRNAs 的胃癌预后signature 的构建及其临床意义。
Libyan J Med. 2023 Dec;18(1):2220153. doi: 10.1080/19932820.2023.2220153.
5
The function of lncRNA EMX2OS/miR-653-5p and its regulatory mechanism in lung adenocarcinoma.lncRNA EMX2OS/miR-653-5p在肺腺癌中的作用及其调控机制
Open Med (Wars). 2023 Apr 10;18(1):20230686. doi: 10.1515/med-2023-0686. eCollection 2023.
6
Comprehensive analysis of necroptosis-related long noncoding RNA to predict prognosis, immune status, and immunotherapeutic response in clear cell renal cell carcinoma.对坏死性凋亡相关长链非编码RNA进行综合分析,以预测透明细胞肾细胞癌的预后、免疫状态和免疫治疗反应。
Transl Cancer Res. 2022 Dec;11(12):4254-4271. doi: 10.21037/tcr-22-1764.
7
Long Non-Coding RNAs as Epigenetic Regulators of Immune Checkpoints in Cancer Immunity.长链非编码RNA作为癌症免疫中免疫检查点的表观遗传调控因子
Cancers (Basel). 2022 Dec 28;15(1):184. doi: 10.3390/cancers15010184.
8
Emerging Role of Enhancer RNAs as Potential Diagnostic and Prognostic Biomarkers in Cancer.增强子RNA作为癌症潜在诊断和预后生物标志物的新兴作用
Noncoding RNA. 2022 Oct 1;8(5):66. doi: 10.3390/ncrna8050066.
9
Emerging Roles and Potential Applications of Non-Coding RNAs in Cervical Cancer.非编码 RNA 在宫颈癌中的新兴作用和潜在应用。
Genes (Basel). 2022 Jul 15;13(7):1254. doi: 10.3390/genes13071254.